Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Update

Pulmatrix, Inc. (NASDAQ:PULM) was the recipient of a large decline in short interest in September. As of September 30th, there was short interest totalling 5,100 shares, a decline of 20.3% from the September 15th total of 6,400 shares. Based on an average trading volume of 11,000 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.1% of the company’s stock are short sold.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on shares of Pulmatrix in a report on Wednesday, October 9th. They issued a “hold” rating for the company.

Pulmatrix Trading Down 0.6 %

NASDAQ PULM traded down $0.01 during trading on Monday, reaching $2.11. 1,992 shares of the company’s stock were exchanged, compared to its average volume of 13,587. Pulmatrix has a fifty-two week low of $1.55 and a fifty-two week high of $2.75. The firm has a market capitalization of $7.70 million, a PE ratio of -0.71 and a beta of 1.00. The company’s fifty day simple moving average is $2.09 and its 200-day simple moving average is $2.01.

Pulmatrix (NASDAQ:PULM) last posted its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share for the quarter. The company had revenue of $1.55 million during the quarter. Pulmatrix had a negative return on equity of 46.86% and a negative net margin of 95.18%.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.